Next Chapter In The Amylin Chronicles: Job Cuts, Restructuring
This article was originally published in The Pink Sheet Daily
Executive Summary
Troubled by slower Byetta growth and uncertainty around the development of a long-acting version, Amylin will cut 25 percent of its San Diego workforce.
You may also be interested in...
Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps
Label with expanded language about thyroid cancer risk is expected.
Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps
Label with expanded language about thyroid cancer risk is expected.
Amylin Speculation Intensifies: Byetta LAR May Be Delayed
Comparability studies could mean filing is impossible for first half of 2009, Amylin says.